The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
Full text
Figure
Related documents
We developed a Markov model using the decision analysis software TreeAge[7] to simulate the progression of neo- vascular age-related macular degeneration in patients in the
[ 41 ] for ANCHOR, MARINA and PDT photodynamic therapy with verteporfin, Overall numbers from a meta- analysis (Wong et al. Ophthalmology 2008;115:1524), AREDS Age-Related
(2 more authors) (2016) Simulation Modelling in Ophthalmology : Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related
Purpose: To evaluate the effect of repeated intravitreal ranibizumab injections for neovascular age related macular degeneration (nAMD) on the retinal nerve fiber layer
Background: The aim of this study was to describe bilateral visual outcomes and the effect of incomplete follow-up after 3 years of ranibizumab therapy for neovascular
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age- Related Macular Degeneration (AMD) (VIEW 1). Vascular Endothelial Growth
The results of the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) and Anti- VEGF Antibody for the Treatment
The other factors that were recorded were the demo- graphic data, duration of AMD, number of appointments, number of ranibizumab injections, visual acuity of both eyes
